Berkeley Catalyst Fund has helped close a $90m series B round for 4D Molecular Therapeutics, which emerged out of UC Berkeley.
Oxford Sciences Innovation has contributed to a series B round for Evox Therapeutics, a spinout of University of Oxford that has also added GV as a shareholder.
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.
Biontech, an immunotherapy spinout of Johannes Gutenberg University Mainz, has received an undisclosed amount of equity funding as part of a collaboration deal that could reach $425m.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.